PURE Bioscience (OTCMKTS:PURE) Sees Large Growth in Short Interest

Posted by Lauren Steadman on Aug 15th, 2026

PURE Bioscience (OTCMKTS:PURE – Get Free Report) saw a large increase in short interest during the month of July. As of July 31st, there was short interest totaling 7,738 shares, an increase of 100.2% from the July 15th total of 3,865 shares. Based on an average daily volume of 32,276 shares, the short-interest ratio is presently 0.2 days. Currently, 0.0% of the company’s stock are short sold.

PURE Bioscience Stock Performance

OTCMKTS:PURE opened at $0.08 on Friday. The company has a market capitalization of $10.40 million, a P/E ratio of -2.67 and a beta of 0.21. The stock’s 50 day moving average price is $0.07 and its 200 day moving average price is $0.07. PURE Bioscience has a 52 week low of $0.04 and a 52 week high of $0.14.

PURE Bioscience (OTCMKTS:PURE – Get Free Report) last announced its quarterly earnings results on Monday, June 15th. The company reported ($0.01) EPS for the quarter. The firm had revenue of $0.51 million for the quarter.

PURE Bioscience Company Profile

(Get Free Report)

PURE Bioscience, Inc is a San Diego, California–based company that develops and markets patented antimicrobial solutions for diverse industries. At the core of its technology portfolio is Silver Dihydrogen Citrate (SDC), an EPA-registered broad-spectrum biocide designed to neutralize bacteria, viruses, and fungi on contact. The company targets applications in food processing, water treatment, personal care, and medical device sanitation.

PURE’s product suite includes concentrate formulations and ready-to-use solutions.